Abstract
In this issue of Blood, Kochenderfer et al show that engineered CD19–chimeric antigen receptor (CAR) and donor-derived allogeneic T cells can safely treat CD19-positive B-cell malignancies, which have relapsed after allogeneic stem cell transplantation.
MeSH terms
-
Antigens, CD19*
-
Female
-
Humans
-
Lymphocyte Transfusion*
-
Lymphoma, B-Cell / therapy*
-
Male
-
Receptors, Antigen, T-Cell / biosynthesis*
-
Stem Cell Transplantation*
-
T-Lymphocytes / metabolism*
-
T-Lymphocytes / transplantation*
Substances
-
Antigens, CD19
-
Receptors, Antigen, T-Cell